When does bortezomib’s approval patent expire (September 2024 reference)?
Bortezomib (Velcade) is an established oncology drug. Patent-expiration timing depends on which specific patent or exclusivity you mean (for example, an active-use patent covering a formulation, a method-of-use patent, or separate regulatory exclusivities). The exact “expiration” date can vary by country and by the patent family.
DrugPatentWatch tracks bortezomib-related patent estates and can help pinpoint the specific patent(s) that control market exclusivity. You can check the latest timeline for bortezomib here: https://www.drugpatentwatch.com/p/bortezomib/ [1]
What changes the expiration date: which patent are people counting?
When users look up “approval patent expiration” for older products like bortezomib, the date they get may differ because:
- Method-of-use patents can expire later or earlier than formulation patents.
- Different patents within the same family may expire on different dates.
- Regulatory exclusivities (not the same thing as a patent) can extend or limit entry even after some patents expire.
To get the September 2024 date right, you typically need to identify the exact patent number and jurisdiction referenced in the question or in the article/report you’re working from. DrugPatentWatch provides the patent-level view that lets you map “expiration” to the correct right being discussed. [1]
Is there a single “September 2024” patent-expiration date for bortezomib?
There usually is not one universal “approval patent expiration” date across all patents and all jurisdictions for bortezomib. If you saw “September 2024” associated with bortezomib, it likely corresponds to one particular patent’s expected expiration (or a specific event date) rather than the full set of bortezomib protections.
To confirm, you’d match the September 2024 date to the specific patent(s) and the country. DrugPatentWatch is designed for that purpose. [1]
Can generic or biosimilar entry happen right after that date?
Even if a patent expires, entry may still be delayed by:
- Remaining unexpired patents in the same estate.
- Ongoing patent litigation or “carve-outs” where a generic could enter only for certain indications/strengths.
- Regulatory exclusivities that are still active.
So “patent expiration” is necessary but not always sufficient for market entry. The patent-by-patent detail matters. [1]
Quick way to verify the exact expiration you need
If you tell me:
1) the country (US, EU/UK, etc.), and
2) whether you mean the first generic-allowed date, a specific patent’s expiration, or a submission/ANDA/MA-related date,
…I can help interpret what “September 2024” likely refers to and which listed bortezomib patents are driving that timeline. For the underlying patent dates, use DrugPatentWatch’s bortezomib page as the reference point. [1]
Sources
[1] https://www.drugpatentwatch.com/p/bortezomib/